🔖
Bu Makaleye Atıf Yap
TİRYAKİOĞLU, O., AKTÜRK, F., MEHMETOĞLU, E., KENAR, S. T., KUMBAY, E. (2022). Moksifloksasin'e bağlı Torsades de Pointes. Anadolu Kardiyoloji Dergisi, Cilt: 11 - Sayı: 6, 560–562. https://ajindex.com/articles/436559
Dergiler / Anadolu Kardiyoloji Dergisi / 2011 / Cilt: 11 - Sayı: 6
Moksifloksasin'e bağlı Torsades de Pointes
- Sayfa
- 560–562
- Yayın Tarihi
- 2022-10-10
- DOI
- —
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗Kaynakça (8)
- Altın T, Özcan O, Turhan S, Ongun Özdemir A, Akyürek O, Karaoğuz O, Güldal M. Torsades de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 2007; 23: 907-8
- Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817
- Iannini PB. Quinolone-induced QT interval prolongation: a not-sounexpected class effect. J Antimicrob Chemother 2001; 47: 893-4
- Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940-50
- Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21: 301-19
- Koide T, Shiba M, Tanaka K, Muramatsu M, Ishida S, Kondo Y, et al. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases J 2008; 1: 409
- Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45: 415-27
- Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsades de pointes and reverse use-dependence. Circulation 1996; 93: 407-11.